logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On January 9th, HSBC Holdings (00005) spent approximately HK$35.61 million to repurchase 468,800 shares in Hong Kong.

date
17:26 10/01/2025
avatar
GMT Eight
HSBC Holdings (00005) announced that it will repurchase approximately 10,780,500 in the UK on January 9, 2025.
HSBC Holdings (00005) announced that on January 9, 2025, it will spend approximately 10.78 million to repurchase around 135.25 million shares in the UK, and approximately HK$35.6123 million to repurchase about 46.88 million shares in Hong Kong.
Related Articles
HK Stock
Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.
China Stock
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): HRS-5765 tablets obtain drug clinical trial approval notification.
Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.
HK Stock
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.
China Stock
Jiangsu Hengrui Pharmaceuticals (01276): HRS-5765 tablets obtain drug clinical trial approval notification.
HK Stock
RECOMMEND
Deloitte China Reports Three Mega Hong Kong IPOs Among Global Top Five In Q1
Deloitte China Reports Three Mega Hong Kong IPOs Among Global Top Five In Q1
icon
09/04/2026
Token Wave Reshapes China’s Internet Landscape
Token Wave Reshapes China’s Internet Landscape
icon
09/04/2026
State‑Owned Six Banks Saw Consumer Loan Balances Rise Over RMB 55 Billion Last Year, Five Banks Grew Above 16% — Will The Surge Continue In 2026?
State‑Owned Six Banks Saw Consumer Loan Balances Rise Over RMB 55 Billion Last Year, Five Banks Grew Above 16% — Will The Surge Continue In 2026?
icon
09/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.